---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-413090"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2026-10-05T11:00:14+00:00"
generated_at: "2026-10-12T14:43:43.466850+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Alector licenses AL050 GCase program to Genentech for $100M upfront and up to $1.17B milestones

## Summary
- Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050, a brain-penetrant GCase enzyme replacement therapy.
- Alector receives $100 million upfront and is eligible for up to $1.17 billion in development, regulatory, and commercial milestones plus tiered royalties.
- Alector exercised its Spur option and will pay Spur $15 million plus a teens percentage of Genentech milestone and other non-royalty partnering income.
- Preliminary cash and marketable securities were about $138.7 million as of Sept 30, 2026, or $223.7 million pro forma after Genentech upfront and Spur payment.
- The Genentech deal extends Alector's cash runway into 2029; Alector will host an R&D webinar on Oct 13, 2026 for AL137, AL164, and AL062.

## SEC filing metadata
- accession: 0001193125-26-413090
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2026-10-05T11:00:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312526413090/0001193125-26-413090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312526413090/alec-20260930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-413090
- JSON: https://secwatch.observer/filing/0001193125-26-413090.json
- Plain text: https://secwatch.observer/filing/0001193125-26-413090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.